JP2000336068A - New carboxylic acid derivative and its preparation - Google Patents
New carboxylic acid derivative and its preparationInfo
- Publication number
- JP2000336068A JP2000336068A JP2000044940A JP2000044940A JP2000336068A JP 2000336068 A JP2000336068 A JP 2000336068A JP 2000044940 A JP2000044940 A JP 2000044940A JP 2000044940 A JP2000044940 A JP 2000044940A JP 2000336068 A JP2000336068 A JP 2000336068A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- aryl
- cycloalkyl
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 15
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims abstract description 6
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical class O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000001590 oxidative effect Effects 0.000 claims abstract description 3
- -1 bicyclic compound Chemical class 0.000 claims description 34
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 30
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 2
- KPNFHMCCBRGOKU-UHFFFAOYSA-N bicyclo[3.1.0]hexane-6-carboxylic acid Chemical class C1CCC2C(C(=O)O)C21 KPNFHMCCBRGOKU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 2
- 150000001923 cyclic compounds Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 29
- 238000003786 synthesis reaction Methods 0.000 abstract description 15
- 125000006239 protecting group Chemical group 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 201000000980 schizophrenia Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000007858 starting material Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- JUIOQBDYJXJVSZ-UHFFFAOYSA-N 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid Chemical class C1CC(=O)C2C(C(=O)O)C21 JUIOQBDYJXJVSZ-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- XHBZYLUDOIQPFQ-UHFFFAOYSA-N 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical compound OC(=O)C1(N)CC(=O)C2C(C(O)=O)C12 XHBZYLUDOIQPFQ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000001469 hydantoins Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 4
- ANUFAWHRSIJTHW-UHFFFAOYSA-N 2-methylheptanedioic acid Chemical compound OC(=O)C(C)CCCCC(O)=O ANUFAWHRSIJTHW-UHFFFAOYSA-N 0.000 description 4
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical class NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 4
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 3
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical compound CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical class 0.000 description 2
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000029033 Spinal Cord disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 2
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 2
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 208000021245 head disease Diseases 0.000 description 2
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 description 1
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FNKSTXGVEUSZJJ-UHFFFAOYSA-N 3-methyl-1,3-oxazolidine Chemical compound CN1CCOC1 FNKSTXGVEUSZJJ-UHFFFAOYSA-N 0.000 description 1
- DHNDDRBMUVFQIZ-UHFFFAOYSA-N 4-hydroxycyclopent-2-en-1-one Chemical compound OC1CC(=O)C=C1 DHNDDRBMUVFQIZ-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- SFLGIMGLWCVAHP-UHFFFAOYSA-N 5h-oxathiole Chemical compound C1OSC=C1 SFLGIMGLWCVAHP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 238000006027 Birch reduction reaction Methods 0.000 description 1
- 238000006150 Bucherer-Bergs reaction Methods 0.000 description 1
- 102000001324 CD59 Antigens Human genes 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 238000006809 Jones oxidation reaction Methods 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- FGQQYAOKQXRHEJ-UHFFFAOYSA-N N.N.[Ce+3] Chemical compound N.N.[Ce+3] FGQQYAOKQXRHEJ-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 241000748228 Porophyllum gracile Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006226 butoxyethyl group Chemical group 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- XIPRKGRYLQHWDN-UHFFFAOYSA-N ethyl 4-[tert-butyl(dimethyl)silyl]oxy-2-oxobicyclo[3.1.0]hexane-6-carboxylate Chemical compound O=C1CC(O[Si](C)(C)C(C)(C)C)C2C1C2C(=O)OCC XIPRKGRYLQHWDN-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000006229 isopropoxyethyl group Chemical group [H]C([H])([H])C([H])(OC([H])([H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 1
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、2−オキソビシク
ロ[3.1.0]ヘキサン−6−カルボン酸誘導体及び
その製造方法に関する。[0001] The present invention relates to a 2-oxobicyclo [3.1.0] hexane-6-carboxylic acid derivative and a method for producing the same.
【0002】[0002]
【従来の技術】グルタミン酸受容体の一種であるメタボ
ロトピックグルタミン酸受容体は薬理学的に3つのグル
ープに分類されている。その中で、グループ2(mGl
uR2/mGluR3)は、アデニルサイクラーゼと結
合し、サイクリックアデノシン1リン酸(cAMP)の
ホルスコリン刺激性の蓄積を抑制する(Trends Pharmac
ol. Sci., 14 13(1993))ことから、グループ2メタボ
ロトピックグルタミン酸受容体に作用する化合物は精神
分裂病、不安及びその関連疾患、うつ病、二極性障害、
てんかん等の精神医学的障害、例えば薬物依存症、認知
障害、アルツハイマー病、ハンチントン舞踏病、パーキ
ンソン病、筋硬直に伴う運動障害、脳虚血、脳不全、脊
髄障害、頭部障害等の神経学的疾患に治療効果および予
防効果を有するとされている。2. Description of the Related Art Metabolotopic glutamate receptors, which are a kind of glutamate receptors, are classified pharmacologically into three groups. Group 2 (mGl
uR2 / mGluR3) binds adenyl cyclase and inhibits forskolin-stimulated accumulation of cyclic adenosine monophosphate (cAMP) (Trends Pharmac
ol. Sci., 14 13 (1993)), compounds that act on the group 2 metabolic topic glutamate receptor are schizophrenia, anxiety and related diseases, depression, bipolar disorder,
Psychiatric disorders such as epilepsy, such as drug addiction, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, motor disorders associated with muscle stiffness, cerebral ischemia, cerebral insufficiency, spinal cord disorders, head disorders and other neurology. It is said to have a therapeutic effect and a preventive effect on experimental diseases.
【0003】本発明者らは、グループ2メタボトロピッ
クグルタミン酸受容体に作用する有用な化合物の一つと
して、2−アミノ−4−オキソビシクロ[3.1.0]
ヘキサン−2,6−ジカルボン酸(7)を発明した(特
願平10−246344号)。特願平10−24634
4号明細書には、その製造方法として、下記に示すごと
く、エノン誘導体(8)にベンジルアルコールを付加して
ベンジルオキシ化合物(9)とした後、ヒダントイン化
によってこれをヒダントイン誘導体(10)とし、次い
で脱ベンジル化、酸化及びチオケタール化によってチオ
ケタール−ヒダントイン誘導体(11)に変換し、更
に、加水分解する合成法が提案されている(下記反応式
中、R2、R3及びR5は同一又は異なって炭素数1−1
0の低級アルキル基を示す。ただし、R2及びR3は一緒
になって−(CH2)n−(nは2又は3)を示すことが
ある)。The present inventors have proposed that one of the useful compounds acting on the group 2 metabotropic glutamate receptor is 2-amino-4-oxobicyclo [3.1.0].
Hexane-2,6-dicarboxylic acid (7) was invented (Japanese Patent Application No. 10-246344). Japanese Patent Application No. Hei 10-24634
In the specification of Patent No. 4, as a production method, as shown below, benzyl alcohol is added to an enone derivative (8) to form a benzyloxy compound (9), and this is converted into a hydantoin derivative (10) by hydantoinization. Then, a synthesis method has been proposed in which the compound is converted to a thioketal-hydantoin derivative (11) by debenzylation, oxidation and thioketalization and further hydrolyzed (in the following reaction formula, R 2 , R 3 and R 5 are the same). Or differently, carbon number 1-1
0 represents a lower alkyl group. However, R 2 and R 3 together may represent-(CH 2 ) n- (n is 2 or 3).
【化6】 Embedded image
【0004】[0004]
【発明が解決しようとする課題】本発明の目的は、精神
分裂病、不安及びその関連疾患、うつ病、二極性障害、
てんかん等の精神医学的障害、更に、薬物依存症、認知
障害、アルツハイマー病、ハンチントン舞踏病、パーキ
ンソン病、筋硬直に伴う運動障害、脳虚血、脳不全、脊
髄障害、頭部障害等の神経学的疾患に治療効果および予
防効果を有するグループ2メタボトロピックグルタミン
酸受容体に作用する2−アミノ−4−オキソビシクロ
[3.1.0]ヘキサン−2,6−ジカルボン酸の効率
的な合成に有用な新規合成中間体及びその製造方法を提
供することにある。SUMMARY OF THE INVENTION It is an object of the present invention to provide schizophrenia, anxiety and related disorders, depression, bipolar disorder,
Psychiatric disorders such as epilepsy, as well as nervous disorders such as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscle stiffness, cerebral ischemia, cerebral insufficiency, spinal cord disorders, and head disorders. For efficient synthesis of 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid acting on group 2 metabotropic glutamate receptor having therapeutic and preventive effects on biological diseases An object of the present invention is to provide a useful novel synthetic intermediate and a method for producing the same.
【0005】[0005]
【課題を解決するための手段】本発明者らは、鋭意検討
した結果、フルフリルアルコールより容易に供給される
4−ヒドロキシ−2−シクロペンテノン又はその水酸基
を保護したタイプの化合物を出発原料として得られる、
2−オキソビシクロ[3.1.0]ヘキサン−6−カル
ボン酸誘導体(1)が、2−アミノ−4−オキソビシク
ロ[3.1.0]ヘキサン−2,6−ジカルボン酸(7)
の効率的な合成に有用であることを見出し、本発明を完
成した。The present inventors have conducted intensive studies and have found that 4-hydroxy-2-cyclopentenone or a compound in which the hydroxyl group is protected, which is easily supplied from furfuryl alcohol, is used as a starting material. Obtained as
2-oxobicyclo [3.1.0] hexane-6-carboxylic acid derivative (1) is converted to 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (7).
The present invention was found to be useful for efficient synthesis of
【0006】すなわち、本発明の1つの形態は、式(1)[0006] That is, one embodiment of the present invention is represented by the following formula (1).
【化7】 [式中、R1は水素原子、C1〜C6アルキル基、C3〜C
6シクロアルキル基、C3〜C6シクロアルキルC1〜C6
アルキル基、アリール基、アリールC1〜C6アルキル
基、C1〜C6アルコキシC1〜C6アルキル基、C1〜C6
ヒドロキシアルキル基、C1〜C6アルキルチオC1〜C6
アルキル基、C1〜C6メルカプトアルキル基、テトラヒ
ドロフラニル基又はテトラヒドロピラニル基を示す。R
2とR3は同一又は異なってC1〜C6アルキル基、C3〜
C6シクロアルキル基、C3〜C6シクロアルキルC1〜C
6アルキル基、アリール基又はアリールC1〜C6アルキ
ル基を示すか、或いは一緒になって−(CH2)n−(n
は2又は3)を示す。Y1及びY2は同一又は異なって硫
黄原子、酸素原子又は窒素原子を示す。]で表される2
−オキソビシクロ[3.1.0]ヘキサン−6−カルボ
ン酸誘導体である。Embedded image [Wherein, R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 3 -C
6 cycloalkyl groups, C 3 -C 6 cycloalkyl C 1 -C 6
Alkyl group, aryl group, aryl C 1 -C 6 alkyl group, C 1 -C 6 alkoxy C 1 -C 6 alkyl group, C 1 -C 6
Hydroxyalkyl group, C 1 -C 6 alkylthio C 1 -C 6
It represents an alkyl group, a C 1 -C 6 mercaptoalkyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group. R
2 and R 3 are identical or different C 1 -C 6 alkyl group, C 3 ~
C 6 cycloalkyl group, C 3 -C 6 cycloalkyl C 1 -C
A 6 alkyl group, an aryl group or an aryl C 1 -C 6 alkyl group, or together form — (CH 2 ) n — (n
Represents 2 or 3). Y 1 and Y 2 are the same or different and represent a sulfur atom, an oxygen atom or a nitrogen atom. 2]
-Oxobicyclo [3.1.0] hexane-6-carboxylic acid derivative.
【0007】また、本発明の他の形態は、式(2)Another aspect of the present invention is a method of formula (2)
【化8】 [式中、R4は水素原子又は水酸基の保護基を示す。]
で表されるシクロペンテノン誘導体に、Me2S=CHC
O2R5[式中、R5はC1〜C6アルキル基、C3〜C6シ
クロアルキル基、C3〜C6シクロアルキルC1〜C6アル
キル基、アリール基、アリールC1〜C6アルキル基、C
1〜C6アルコキシC1〜C6アルキル基、C 1〜C6ヒドロ
キシアルキル基、C1〜C6アルキルチオC1〜C6アルキ
ル基、C1〜C6メルカプトアルキル基、テトラヒドロフ
ラニル基又はテトラヒドロピラニル基を示す。]で表さ
れるスルホニウムイリドを反応させるか、又は、Me2S
+CH2CO2R5・X-[式中、R5は前記と同様である。
Xは塩素原子、臭素原子又はヨウ素原子を示す。]で表
されるスルホニウム塩を反応させることによって、式
(3)Embedded image[Wherein, RFourRepresents a hydrogen atom or a hydroxyl-protecting group. ]
To the cyclopentenone derivative represented byTwoS = CHC
OTwoRFive[Wherein, RFiveIs C1~ C6Alkyl group, CThree~ C6Shi
Chloroalkyl group, CThree~ C6Cycloalkyl C1~ C6Al
Kill group, aryl group, aryl C1~ C6Alkyl group, C
1~ C6Alkoxy C1~ C6Alkyl group, C 1~ C6Hydro
Xyalkyl group, C1~ C6Alkylthio C1~ C6Archi
Group, C1~ C6Mercaptoalkyl group, tetrahydrof
It represents a lanyl group or a tetrahydropyranyl group. ]
Or reacting the sulfonium ylideTwoS
+CHTwoCOTwoRFive・ X-[Wherein, RFiveIs the same as above.
X represents a chlorine atom, a bromine atom or an iodine atom. ]
By reacting the sulfonium salt
(3)
【化9】 [式中、R4、R5は前記と同様である。]で表される二
環式化合物とする工程と、前記二環式化合物のカルボニ
ル基を保護することによって、式(4)Embedded image Wherein R 4 and R 5 are the same as above. And the step of protecting the carbonyl group of the bicyclic compound to obtain a compound of the formula (4)
【化10】 [式中、R2とR3は同一又は異なってC1〜C6アルキル
基、C3〜C6シクロアルキル基、C3〜C6シクロアルキ
ルC1〜C6アルキル基、アリール基又はアリールC1〜
C6アルキル基を示すか、或いは一緒になって−(C
H2)n−(nは2又は3)を示す。Y1及びY2は同一又
は異なって硫黄原子、酸素原子又は窒素原子を示す。R
4及びR5は前記と同様である。]で表される誘導体とす
る工程と、前記誘導体のR4が水素原子以外の場合はR4
を水素原子に変換後、前記誘導体を酸化する工程とを含
む、2−オキソビシクロ[3.1.0]ヘキサン−6−
カルボン酸誘導体(1)の製造方法である。Embedded image Wherein R 2 and R 3 are the same or different and are a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, a C 3 -C 6 cycloalkyl C 1 -C 6 alkyl group, an aryl group or an aryl C 1-
Represents a C 6 alkyl group or together forms — (C
H 2 ) n- (n is 2 or 3). Y 1 and Y 2 are the same or different and represent a sulfur atom, an oxygen atom or a nitrogen atom. R
4 and R 5 are the same as described above. A step of a derivative represented by, otherwise R 4 is a hydrogen atom of the derivative R 4
Converting the compound to a hydrogen atom and then oxidizing the derivative. 2-oxobicyclo [3.1.0] hexane-6-
This is a method for producing the carboxylic acid derivative (1).
【0008】そして、本発明の更に他の形態は、カルボ
ン酸誘導体(1)から得ることができる式(5)[0008] Still another embodiment of the present invention provides a compound of the formula (5) which can be obtained from the carboxylic acid derivative (1).
【化11】 [式中、R1は水素原子、C1〜C6アルキル基、C3〜C
6シクロアルキル基、C3〜C6シクロアルキルC1〜C6
アルキル基、アリール基、アリールC1〜C6アルキル
基、C1〜C6アルコキシC1〜C6アルキル基、C1〜C6
ヒドロキシアルキル基、C1〜C6アルキルチオC1〜C6
アルキル基、C1〜C6メルカプトアルキル基、テトラヒ
ドロフラニル基又はテトラヒドロピラニル基を示す。R
2とR3は同一又は異なってC1〜C6アルキル基、C3〜
C6シクロアルキル基、C3〜C6シクロアルキルC1〜C
6アルキル基、アリール基又はアリールC1〜C6アルキ
ル基を示すか、或いは一緒になって−(CH2)n−(n
は2又は3)を示す。Y1及びY2は同一又は異なって硫
黄原子、酸素原子又は窒素原子を示す。]で表されるビ
シクロ[3.1.0]ヘキサン−6−カルボン酸誘導体
である。Embedded image [Wherein, R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 3 -C
6 cycloalkyl groups, C 3 -C 6 cycloalkyl C 1 -C 6
Alkyl group, aryl group, aryl C 1 -C 6 alkyl group, C 1 -C 6 alkoxy C 1 -C 6 alkyl group, C 1 -C 6
Hydroxyalkyl group, C 1 -C 6 alkylthio C 1 -C 6
It represents an alkyl group, a C 1 -C 6 mercaptoalkyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group. R
2 and R 3 are identical or different C 1 -C 6 alkyl group, C 3 ~
C 6 cycloalkyl group, C 3 -C 6 cycloalkyl C 1 -C
A 6 alkyl group, an aryl group or an aryl C 1 -C 6 alkyl group, or together form — (CH 2 ) n — (n
Represents 2 or 3). Y 1 and Y 2 are the same or different and represent a sulfur atom, an oxygen atom or a nitrogen atom. And a bicyclo [3.1.0] hexane-6-carboxylic acid derivative represented by the following formula:
【0009】本発明において使用される用語が以下に定
義される。本発明において、「Cn〜Cm」とは、その後
に続く基がn〜m個の炭素原子を有することを示す。The terms used in the present invention are defined below. In the present invention, “C n -C m ” indicates that the following group has nm carbon atoms.
【0010】C1〜C6アルキル基は、炭素原子を1〜6
個有する直鎖状又は分岐鎖状のアルキル基を示し、例え
ばメチル基、エチル基、プロピル基、イソプロピル基、
ブチル基、イソブチル基、t−ブチル基、ペンチル基、
イソペンチル基、ヘキシル基、イソヘキシル基などであ
る。A C 1 -C 6 alkyl group has 1 to 6 carbon atoms.
Represents a linear or branched alkyl group having, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group,
Butyl group, isobutyl group, t-butyl group, pentyl group,
And isopentyl, hexyl, and isohexyl groups.
【0011】C3〜C6シクロアルキル基は、炭素原子を
3〜6個有する環状アルキル基を示し、例えばシクロプ
ロピル基、シクロペンチル基、シクロヘキシル基などで
ある。The C 3 -C 6 cycloalkyl group is a cyclic alkyl group having 3 to 6 carbon atoms, such as a cyclopropyl group, a cyclopentyl group and a cyclohexyl group.
【0012】C3〜C6シクロアルキルC1〜C6アルキル
基は、C3〜C6シクロアルキル基とC1〜C6アルキル基
の複合した形態を有しており、例えばシクロプロピルメ
チル基、シクロブチルメチル基、シクロペンチルメチル
基、シクロヘキシルメチル基などである。The C 3 -C 6 cycloalkyl C 1 -C 6 alkyl group has a complex form of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkyl group, for example, a cyclopropylmethyl group. , Cyclobutylmethyl group, cyclopentylmethyl group, cyclohexylmethyl group and the like.
【0013】アリール基は、フェニル基、ナフチル基等
であり、好ましくはフェニル基である。アリールC1〜
C6アルキル基は、少なくとも1つ以上のアリール基、
好ましくはフェニル基、で置換された、炭素原子を1〜
6個有する直鎖状又は分岐鎖状のアルキル基を示し、例
えばベンジル基、ジフェニルメチル基、1−フェニルエ
チル基、2−フェニルエチル基などである。The aryl group is a phenyl group, a naphthyl group or the like, and is preferably a phenyl group. Aryl C 1-
A C 6 alkyl group is at least one or more aryl groups;
A phenyl group, preferably substituted with 1 to 1 carbon atoms
It represents a linear or branched alkyl group having six, such as a benzyl group, a diphenylmethyl group, a 1-phenylethyl group, and a 2-phenylethyl group.
【0014】C1〜C6アルコキシC1〜C6アルキル基
は、C1〜C6アルコキシ基とC1〜C6アルキル基の複合
した形態を有している。ここで、C1〜C6アルコキシ基
とは、炭素原子を1〜6個有する直鎖状又は分岐鎖状の
アルコキシ基を指し、例えば、メトキシ基、エトキシ
基、プロポキシ基、イソプロポキシ基、ブトキシ基、イ
ソブトキシ基、t−ブトキシ基、ペンチルオキシ基、イ
ソペンチルオキシ基などである。したがって、C1〜C6
アルコキシC1〜C6アルキル基の例には、メトキシメチ
ル基、エトキシメチル基、メトキシエチル基、エトキシ
エチル基、プロポキシエチル基、イソプロポキシエチル
基、ブトキシエチル基、イソブトキシエチル基、ペンチ
ルオキシエチル基、イソペンチルオキシエチル基などが
含まれる。The C 1 -C 6 alkoxy C 1 -C 6 alkyl group has a complex form of a C 1 -C 6 alkoxy group and a C 1 -C 6 alkyl group. Here, the C 1 -C 6 alkoxy group refers to a linear or branched alkoxy group having 1 to 6 carbon atoms, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group. Group, isobutoxy group, t-butoxy group, pentyloxy group, isopentyloxy group and the like. Therefore, C 1 to C 6
Examples of alkoxy C 1 -C 6 alkyl groups include methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, isopropoxyethyl, butoxyethyl, isobutoxyethyl, pentyloxyethyl Group, isopentyloxyethyl group and the like.
【0015】C1〜C6ヒドロキシアルキル基は、少なく
とも1つのヒドロキシル基で置換されたC1〜C6アルキ
ル基を示す。したがって、C1〜C6ヒドロキシアルキル
基の例には、2−ヒドロキシエチル基、3−ヒドロキシ
プロピル基、2,3−ジヒドロキシプロピル基などが含
まれる。The C 1 -C 6 hydroxyalkyl group represents a C 1 -C 6 alkyl group substituted with at least one hydroxyl group. Accordingly, examples of the C 1 -C 6 hydroxyalkyl group include a 2-hydroxyethyl group, a 3-hydroxypropyl group, a 2,3-dihydroxypropyl group, and the like.
【0016】C1〜C6アルキルチオC1〜C6アルキル基
は、C1〜C6アルキルチオ基とC1〜C6アルキル基の複
合した形態を有している。ここで、C1〜C6アルキルチ
オ基とは、炭素原子を1〜6個有する直鎖状又は分岐鎖
状のアルキルチオ基を指し、例えば、メチルチオ基、エ
チルチオ基、プロピルチオ基、イソプロピルチオ基、ブ
チルチオ基、イソブチルチオ基、t−ブチルチオ基、ペ
ンチルチオ基、イソペンチルチオ基などである。したが
って、C1〜C6アルキルチオC1〜C6アルキル基の例に
は、メチルチオメチル基、2−メチルチオエチル基など
が含まれる。The C 1 -C 6 alkylthio C 1 -C 6 alkyl group has a complex form of a C 1 -C 6 alkylthio group and a C 1 -C 6 alkyl group. Here, the C 1 -C 6 alkylthio group refers to a linear or branched alkylthio group having 1 to 6 carbon atoms, such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, and a butylthio group. Group, isobutylthio group, t-butylthio group, pentylthio group, isopentylthio group and the like. Accordingly, examples of the C 1 -C 6 alkylthio C 1 -C 6 alkyl group include a methylthiomethyl group, a 2-methylthioethyl group, and the like.
【0017】C1〜C6メルカプトアルキル基は、少なく
とも1つのメルカプト基で置換されたC1〜C6アルキル
基を示す。したがって、C1〜C6メルカプトアルキル基
の例には、2−メルカプトエチル基、3−メルカプトプ
ロピル基、2,3−ジメルカプトプロピル基などが含ま
れる。The C 1 -C 6 mercaptoalkyl group represents a C 1 -C 6 alkyl group substituted with at least one mercapto group. Accordingly, examples of the C 1 -C 6 mercaptoalkyl group include a 2-mercaptoethyl group, a 3-mercaptopropyl group, a 2,3-dimercaptopropyl group, and the like.
【0018】上記した各種の基は、その基上の少なくと
も1つの水素原子が、例えば、フッ素原子、塩素原子、
臭素原子、ヨウ素原子等のハロゲン原子;ニトロ基;ア
ミノ基;ヒドロキシル基;チオール基;ホルミル基;カ
ルボキシル基;シアノ基;カルバモイル基;メチル基、
エチル基、プロピル基、イソプロピル基、ブチル基、イ
ソブチル基、sec-ブチル基、tert-ブチル基、ペンチル
基、イソペンチル基、ネオペンチル基、tert-ペンチル
基等のアルキル基;フェニル基、ナフチル基、ビフェニ
ル基、アントラニル基、ピロリル基、ピリジル基、チエ
ニル基等のアリール基及び複素環基;メトキシカルボニ
ル基、エトキシカルボニル基等のアルコキシカルボニル
基;アセチル基、ベンゾイル基等のアシル基;メトキシ
基、エトキシ基、プロポキシ基等のアルコキシ基;メチ
ルチオ基、エチルチオ基、プロピルチオ基等のアルキル
チオ基;等の非水素原子又は基によって置換されていて
もよい。したがって、例えば、2,2,2−トリクロロ
エチル基、フェナシル基、2,6−ジメチルシクロヘキ
シル基及び4−メトキシベンジル基などもR1及びR2の
範囲に含まれる。なお、これらの置換基中の炭素原子数
は上記したn又はmには含まれない。In the various groups described above, at least one hydrogen atom on the group is, for example, a fluorine atom, a chlorine atom,
A halogen atom such as a bromine atom or an iodine atom, a nitro group, an amino group, a hydroxyl group, a thiol group, a formyl group, a carboxyl group, a cyano group, a carbamoyl group, a methyl group,
Alkyl groups such as ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group; phenyl group, naphthyl group, biphenyl Groups, anthranyl groups, pyrrolyl groups, pyridyl groups, thienyl groups and other aryl groups and heterocyclic groups; methoxycarbonyl groups, ethoxycarbonyl groups and other alkoxycarbonyl groups; acetyl groups, benzoyl groups and other acyl groups; methoxy groups and ethoxy groups , An alkoxythio group such as a propoxy group; an alkylthio group such as a methylthio group, an ethylthio group or a propylthio group; or a non-hydrogen atom or a group. Therefore, for example, R 1 and R 2 also include a 2,2,2-trichloroethyl group, a phenacyl group, a 2,6-dimethylcyclohexyl group, a 4-methoxybenzyl group, and the like. The number of carbon atoms in these substituents is not included in n or m described above.
【0019】本発明において、水酸基の保護基とは、上
記したC1〜C6アルキル基、C3〜C6シクロアルキル
基、C3〜C6シクロアルキルC1〜C6アルキル基、アリ
ール基、アリールC1〜C6アルキル基、C1〜C6アルコ
キシC1〜C6アルキル基、C 1〜C6ヒドロキシアルキル
基、C1〜C6アルキルチオC1〜C6アルキル基、C1〜
C6メルカプトアルキル基、テトラヒドロフラニル基及
びテトラヒドロピラニル基の他に、アシル基又は三置換
シリル基等の一般に使用される保護基を含む。ここで、
アシル基とは炭素数1−6の直鎖状若しくは分岐鎖状の
脂肪族又は芳香族アシル基であり、例えばアセチル基、
ピバロイル基、ベンゾイル基等である。また、三置換シ
リル基とは炭素数1−6のアルキル基又はフェニル基よ
り選択される任意の置換基を3つ有するシリル基であ
り、例えばトリメチルシリル基、トリエチルシリル基、
tert−ブチルジメチルシリル基、tert−ブチルジフェニ
ルシリル基などである。In the present invention, the hydroxyl-protecting group is
C written1~ C6Alkyl group, CThree~ C6Cycloalkyl
Group, CThree~ C6Cycloalkyl C1~ C6Alkyl group, ant
Group, aryl C1~ C6Alkyl group, C1~ C6Arco
Kishi C1~ C6Alkyl group, C 1~ C6Hydroxyalkyl
Group, C1~ C6Alkylthio C1~ C6Alkyl group, C1~
C6Mercaptoalkyl group, tetrahydrofuranyl group and
And tetrahydropyranyl groups, acyl groups or trisubstituted groups
Includes commonly used protecting groups such as silyl groups. here,
An acyl group is a straight or branched chain having 1 to 6 carbon atoms.
An aliphatic or aromatic acyl group, such as an acetyl group,
And pivaloyl and benzoyl groups. In addition, trisubstitution
Ryl is an alkyl or phenyl group having 1 to 6 carbon atoms.
A silyl group having three optional substituents
For example, trimethylsilyl group, triethylsilyl group,
tert-butyldimethylsilyl group, tert-butyldiphenyl
And a lusilyl group.
【0020】式(1)で示される化合物において、R2
−Y1−及びR3−Y2−が同一の基を表す場合、又は、
Y1及びY2が同一でかつR2及びR3が一緒になって−
(CH2)n−(nは2又は3)を表す場合は、1,5
及び6位に3つの不斉炭素原子が存在する。また、Y1
又はY2、或いは、R2又はR3が異なる場合は1,4,
5及び6位に4つの不斉炭素原子が存在する。したがっ
て、本発明の化合物は光学活性体、ラセミ体等のエナン
チオマー混合物又はジアステレオマー混合物として存在
できる。すなわち、本発明の化合物は式(1)で表され
る化合物の光学活性体、ラセミ体等のエナンチオマー混
合物及びジアステレオマー混合物を全て含むものであ
る。In the compound represented by the formula (1), R 2
-Y 1 -and R 3 -Y 2- represent the same group, or
Y 1 and Y 2 are the same and R 2 and R 3 together
(CH 2 ) n- (n is 2 or 3) represents 1,5
And three asymmetric carbon atoms at position 6. Also, Y 1
Or when Y 2 or R 2 or R 3 is different, 1,4
There are four asymmetric carbon atoms at positions 5 and 6. Therefore, the compound of the present invention can exist as an enantiomer mixture such as an optically active substance, a racemate or a diastereomer mixture. That is, the compound of the present invention includes all of the optically active and racemic forms of the compound represented by the formula (1), including enantiomeric mixtures and diastereomeric mixtures.
【0021】[0021]
【発明の実施の形態】本発明に係る式(1)の化合物は以
下の反応によって製造することができる。(下記の反応
式中、R1、R2、R3、R4、R5、Y1及びY2は前記と
同様である。)BEST MODE FOR CARRYING OUT THE INVENTION The compound of the formula (1) according to the present invention can be produced by the following reaction. (In the following reaction formula, R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are the same as described above.)
【化12】 Embedded image
【0022】工程1:フルフリルアルコールより一工程
(R4が水素原子の場合)又は二工程(R4が水素原子以外
の場合)で得られるエノン誘導体(2)(特開昭57−62
236号公報参照)に、予め調製したMe2S=CHCO2
R5で示されるスルホニウムイリド[式中、R5は前記と
同様である。]を不活性溶媒中反応させるか、又は、M
e2S+CH2CO2R5・X-[式中、R5は前記と同様であ
る。Xは塩素原子、臭素原子およびヨウ素原子を示
す。]で表されるスルホニウム塩を不活性溶媒中、塩基
の存在下反応させることによって、二環式化合物(3)を
得る。Step 1: One step from furfuryl alcohol
(When R 4 is a hydrogen atom) or in two steps (when R 4 is other than a hydrogen atom) (2) (JP-A-57-62).
No. 236), the previously prepared Me 2 S = CHCO 2
Sulfonium ylide wherein represented by R 5, R 5 are as defined above. Is reacted in an inert solvent, or M
e 2 S + CH 2 CO 2 R 5 .X − [wherein, R 5 is the same as defined above. X represents a chlorine atom, a bromine atom and an iodine atom. And the reaction is carried out in an inert solvent in the presence of a base to obtain a bicyclic compound (3).
【0023】不活性溶媒としては、例えばベンゼン、ト
ルエン、ヘキサンなどの炭化水素系溶媒、例えばジクロ
ロメタン、クロロホルムなどのハロゲン系溶媒、例えば
テトラヒドロフラン、ジエチルエーテルなどのエーテル
系溶媒、アセトニトリル、又はこれらの混合溶媒等を使
用することができる。また、塩基としては、例えばトリ
エチルアミン、ジイソプロピルエチルアミン、ピリジ
ン、1,8−ジアザビシクロ[5.4.0]−7−ウン
デセンなどの有機塩基類、あるいは、例えば炭酸カリウ
ム、水酸化ナトリウムなどの無機塩基類を使用すること
ができる。本反応は、0−30℃の温度下で行うことが
好ましく、また、Me2S=CHCO2R5で示されるスル
ホニウムイリドを用いる場合には、12時間から3日間
反応させることが好ましい。Examples of the inert solvent include hydrocarbon solvents such as benzene, toluene and hexane; halogen solvents such as dichloromethane and chloroform; ether solvents such as tetrahydrofuran and diethyl ether; acetonitrile; Etc. can be used. Examples of the base include organic bases such as triethylamine, diisopropylethylamine, pyridine and 1,8-diazabicyclo [5.4.0] -7-undecene, and inorganic bases such as potassium carbonate and sodium hydroxide. Can be used. This reaction is preferably performed at a temperature of 0 to 30 ° C. When a sulfonium ylide represented by Me 2 S = CHCO 2 R 5 is used, the reaction is preferably performed for 12 hours to 3 days.
【0024】工程2:二環式化合物(3)のカルボニル基
部位を、Protecting Groups in Organic Synthesis(The
odora W. Greene著、 John Wilely & Sons Inc.)に記載
されるような一般的な方法によって保護し、誘導体
(4)とする。カルボニル基の保護の形態としては、例
えば、ジメチルケタール、ジエチルケタール、1,3−
ジオキサン、1,3−ジオキソラン、S,S'−ジメチル
ケタール、1,3−ジチアン、1,3−ジチオラン、1,
3−オキサチオラン、オキサゾリジン、N−メチルオキ
サゾリジン等の一般的な環状又は非環状の形での保護形
態を採用することができる。Step 2: The carbonyl group site of the bicyclic compound (3) is protected by Protecting Groups in Organic Synthesis (The
The derivative (4) is protected by a general method as described in odora W. Greene, John Wilely & Sons Inc.). Examples of the form of protection of the carbonyl group include, for example, dimethyl ketal, diethyl ketal, 1,3-
Dioxane, 1,3-dioxolan, S, S'-dimethylketal, 1,3-dithiane, 1,3-dithiolan, 1,
Protected forms in the general cyclic or acyclic form, such as 3-oxathiolane, oxazolidine, N-methyloxazolidine, can be employed.
【0025】なお、例えばR4がシリル系保護基等の、
ルイス酸存在下において水素原子と置換容易な保護基の
場合には、例えば三フッ化ホウ素ジエチルエーテル錯体
等のルイス酸の存在下でカルボニル基部位の保護を実施
することによって、同時に、水酸基側の保護基が除去さ
れ、R4=Hとすることができる。For example, when R 4 is a silyl protecting group or the like,
In the case of a protecting group that can be easily replaced with a hydrogen atom in the presence of a Lewis acid, for example, by protecting the carbonyl group site in the presence of a Lewis acid such as boron trifluoride diethyl ether complex, the hydroxyl group side The protecting group may be removed and R 4 HH.
【0026】工程3:誘導体(4)においてR4が水素
原子以外の場合には、水酸基の保護基R4を脱保護して
R4=Hとし、続いて酸化することによって、本発明化
合物である(±)−2−オキソビシクロ[3.1.0]ヘ
キサン−6−カルボン酸誘導体(1)へ誘導することがで
きる。ここで、水酸基の保護基R4の脱保護は、例えば
R4がアシル系保護基の場合は、例えばメタノール、エ
タノール等のアルコール系溶媒、例えばアセトン、メチ
ルエチルケトン等のケトン類、例えばテトラヒドロフラ
ンなどのエーテル系溶媒、水またはこれらの有機溶媒と
の混合溶媒中、例えば炭酸カリウムあるいは水酸化ナト
リウム等の無機塩基存在下において行うことができる。
また、例えばR4がベンジル基の場合は、例えばパラジ
ウムを触媒とした水素添加やバーチ還元等により脱保護
を行うことができる。さらに、例えばR4がシリル系の
保護基の場合は、例えばテトラ−n−ブチルアンモニウ
ムフルオリド等の脱シリル化剤を用いて脱保護を行うこ
とができる( Protecting Groups in Organic Synthesis
(Theodora W. Greene著、 John Wilely & Sons Inc.)参
照)。Step 3: When R 4 is other than a hydrogen atom in the derivative (4), the protecting group R 4 for the hydroxyl group is deprotected to R 4 HH, followed by oxidation to obtain the compound of the present invention. It can be derived to a certain (±) -2-oxobicyclo [3.1.0] hexane-6-carboxylic acid derivative (1). Here, the deprotection of the hydroxyl-protecting group R 4 is performed, for example, when R 4 is an acyl-type protecting group, for example, an alcohol-based solvent such as methanol or ethanol, for example, a ketone such as acetone or methyl ethyl ketone, or an ether such as tetrahydrofuran. The reaction can be carried out in a system solvent, water or a mixed solvent thereof with an organic solvent, for example, in the presence of an inorganic base such as potassium carbonate or sodium hydroxide.
Further, when R 4 is a benzyl group, for example, deprotection can be performed by hydrogenation or Birch reduction using palladium as a catalyst. Further, for example, when R 4 is a silyl-based protecting group, deprotection can be performed using a desilylating agent such as tetra-n-butylammonium fluoride (Protecting Groups in Organic Synthesis).
(See Theodora W. Greene, John Wilely & Sons Inc.)).
【0027】ここで、酸化とは、例えば、Jones酸
化、Collins酸化、又は、ピリジニウムクロロク
ロメート(PCC)、ピリジニウムジクロメート(PDC)
等に代表されるクロム系酸化剤、例えば過マンガン酸カ
リウム、二酸化マンガン等のマンガン系酸化剤、例えば
オギザリルクロライド、無水酢酸、五酸化二リン、スル
ファートリオキサイド−ピリジン等を活性化剤として用
いるジメチルスルホキシド系酸化剤、例えばパラジウ
ム、白金等を触媒として用いる酸素酸化、例えば硝酸二
アンモニウムセリウム、硫酸セリウム等のセリウム系酸
化剤、過ルテニウム酸テトラプロピルアンモニウム、酸
化ルテニウム等のルテニウム系酸化剤、例えばDess
−Martin試薬等(OXIDATIONS IN ORGANIC CHEMIST
RY,AMERICAN CHEMICAL SOCIETY,WASHINGTON,DC,1990,MI
LOS HUDLICKY著 参照)の酸化剤を、例えばテトラヒド
ロフラン、ジエチルエーテルなどのエーテル類、例えば
トルエン、ベンゼンなどの炭化水素類、例えばジクロロ
メタン、クロロホルムなどのハロゲン系溶媒、例えばア
セトン、エチルメチルケトンなどのケトン類、アセトニ
トリル、N,N−ジメチルホルムアミド、酢酸、ピリジ
ン、水、又はこれらの混合溶媒等の不活性溶媒中反応さ
せることを示す。Here, the oxidation means, for example, Jones oxidation, Collins oxidation, or pyridinium chlorochromate (PCC) or pyridinium dichromate (PDC).
Chromium-based oxidizing agents represented by, for example, potassium permanganate, manganese-based oxidizing agents such as manganese dioxide, for example, oxalyl chloride, acetic anhydride, diphosphorus pentoxide, sulfur trioxide-pyridine and the like as an activator Dimethyl sulfoxide-based oxidizing agent used, for example, palladium, oxygen oxidation using platinum or the like as a catalyst, for example, cerium-based oxidizing agent such as diammonium cerium, cerium sulfate, tetrapropylammonium perruthenate, ruthenium-based oxidizing agent such as ruthenium oxide, For example, Dess
-Martin reagents, etc. (OXIDATIONS IN ORGANIC CHEMIST
RY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, 1990, MI
Oxidizing agents such as ethers such as tetrahydrofuran and diethyl ether; hydrocarbons such as toluene and benzene; halogenated solvents such as dichloromethane and chloroform; and ketones such as acetone and ethyl methyl ketone. , Acetonitrile, N, N-dimethylformamide, acetic acid, pyridine, water, or an inert solvent such as a mixed solvent thereof.
【0028】ここで、R1が低級アルキル基又はベンジ
ル基の場合は、酸性又は塩基性条件下でのエステルの加
水分解によってR1を水素原子に変換することができ
る。また、R1がベンジル基の場合は、水素添加によっ
てもR1を水素原子に変換することができる。Here, when R 1 is a lower alkyl group or a benzyl group, R 1 can be converted to a hydrogen atom by hydrolysis of the ester under acidic or basic conditions. Also, if R 1 is a benzyl group, it can also be converted to R 1 a hydrogen atom by hydrogenation.
【0029】(±)体のカルボン酸誘導体(1)は、例えば
セルロースカルバメート誘導体、アミロースカルバメー
ト誘導体などのキラル担体を用いたHPLC法にて(+)
体及び(−)体にそれぞれ光学分割することができる。ま
た、R1が水素原子である(±)体のカルボン酸誘導体
(1)は、例えば(+)又は(−)−1−フェニルエチルアミ
ン、(+)又は(−)−フェニルグリシノール、(+)又は
(−)−2−アミノ−1−ブタノール、(+)又は(−)−ア
ラニノール、ブルシン、シンコニジン、シンコニン、キ
ニン、キニジン、デヒドロアビエチルアミン等の光学活
性なアミン類との塩を用いるか、或いは光学活性な一級
或いは二級アミンとのアミド誘導体に導いても(+)体お
よび(−)体に光学分割することができる。The (±) -form carboxylic acid derivative (1) can be obtained by (+) HPLC method using a chiral carrier such as a cellulose carbamate derivative or an amylose carbamate derivative.
It can be optically divided into a body and a (-) body. Further, a carboxylic acid derivative of the (±) form wherein R 1 is a hydrogen atom
(1) is, for example, (+) or (−)-1-phenylethylamine, (+) or (−)-phenylglycinol, (+) or
Using salts with optically active amines such as (−)-2-amino-1-butanol, (+) or (−)-alaninol, brucine, cinchonidine, cinchonine, quinine, quinidine, dehydroabiethylamine, or Even when an amide derivative with an optically active primary or secondary amine is introduced, it can be optically resolved into (+)-form and (-)-form.
【0030】ところで、2−オキソビシクロ[3.1.
0]ヘキサン−6−カルボン酸誘導体(1)は、下記式に
示されるように、R2−Y1及びR3−Y2の組によって保
護されたカルボニル基部位と無保護のカルボニル基部位
を相互に変換することによって、(−)体のカルボン酸
誘導体(1)を(+)体の(1)と等価の化合物(12)
に変換し、また、(+)体のカルボン酸誘導体(1)を
(−)体の(1)と等価の化合物(12)に変換するこ
とが可能である。(下記式中、R1、R2、R3、Y1及び
Y2は前記と同様であり、R6及びR7はR2及びR3で定
義される基と、Y3及びY4はY1及びY2で定義される基
と同様である。)By the way, 2-oxobicyclo [3.1.
0] The hexane-6-carboxylic acid derivative (1) has a carbonyl group site protected by a pair of R 2 —Y 1 and R 3 —Y 2 and an unprotected carbonyl group site as shown in the following formula. The compound (12) which is equivalent to the (+)-form (1) is obtained by converting the (-)-form carboxylic acid derivative (1) into each other.
And the (+)-form carboxylic acid derivative (1) can be converted to the compound (12) equivalent to the (-)-form (1). (In the following formula, R 1 , R 2 , R 3 , Y 1 and Y 2 are the same as above, R 6 and R 7 are the groups defined by R 2 and R 3 , and Y 3 and Y 4 are It is the same as defined for Y 1 and Y 2. )
【化13】 Embedded image
【0031】すなわち、(±)体より分割された(+)
及び(−)の各光学活性体は、2−アミノ−4−オキソ
ビシクロ[3.1.0]ヘキサン−2,6−ジカルボン
酸(7)の光学活性体の合成において無駄無く利用するこ
とができる。このように、本発明のカルボン酸誘導体
(1)は、光学活性な2−アミノ−4−オキソビシクロ
[3.1.0]ヘキサン−2,6−ジカルボン酸(7)の
合成に極めて有用である。That is, (+) divided from the (±) field
Each of the optically active forms (-) and (-) can be used without waste in the synthesis of the optically active form of 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (7). it can. Thus, the carboxylic acid derivative (1) of the present invention is extremely useful for the synthesis of optically active 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (7). is there.
【0032】この様な変換は例えば以下のようにして行
うことができる。すなわち、例えば一方のカルボニル基
を保護するR2−Y1−とR3−Y2−が一緒になって−S
CH 2CH2S−基を示す場合には、無保護の状態にある
他方のカルボニル基を例えば−OCH2CH2O−基で保
護する一方で、−SCH2CH2S−基の部分のみを選択
的に脱保護する( Protecting Groups in Organic Synth
esis(Theodora W. Greene著、 John Wilely & Sons In
c.)参照)。これにより、当初、−SCH2CH2S−基で
保護されていたカルボニル基は無保護状態となり、一
方、無保護状態であったカルボニル基は−OCH2CH2
O−基によって保護される。このようにして光学活性な
カルボン酸誘導体(1)のカルボニル基の保護位置を変
換することにより、カルボン酸誘導体(1)を無駄なく
利用することができる。Such conversion is performed, for example, as follows.
I can. That is, for example, one carbonyl group
R to protectTwo-Y1-And RThree-YTwo-Together-S
CH TwoCHTwoWhen it represents an S-group, it is unprotected
The other carbonyl group is, for example, -OCHTwoCHTwoO-group
While protecting -SCHTwoCHTwoSelect only S-group
Protecting Groups in Organic Synth
esis (Theodora W. Greene, John Wilely & Sons In
c.)). Thereby, initially, -SCHTwoCHTwoIn the S-group
The protected carbonyl group becomes unprotected and
On the other hand, the unprotected carbonyl group is -OCHTwoCHTwo
Protected by O-group. In this way the optically active
Change the protection position of the carbonyl group of the carboxylic acid derivative (1)
In this way, the carboxylic acid derivative (1) can be used without waste.
Can be used.
【0033】本発明のカルボン酸誘導体(1)は、例え
ば以下の工程を経て、2−アミノ−4−オキソビシクロ
[3.1.0]ヘキサン−2,6−ジカルボン酸(7)
へと変換される。The carboxylic acid derivative (1) of the present invention can be obtained, for example, through the following steps by subjecting it to 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (7).
Is converted to
【0034】工程4:(±)、(+)又は(−)−カルボン酸
誘導体(1)は、ストレッカーアミノ酸合成(Strecker Am
ino Acid Synthesis)(Ann.,75,27(1850);91,349(185
0))、ブッヘラー−ベルグス反応(Bucherer-Bergs React
ion)(J.Prakt.Chem.,140,69(1934))又はこれらの変法に
よって、ヒダントイン誘導体(5)又はアミノシアニド誘
導体(6)に導かれる。Step 4: The (±), (+) or (−)-carboxylic acid derivative (1) is synthesized from Strecker Amino Acid
ino Acid Synthesis) (Ann., 75 , 27 (1850); 91 , 349 (185
0)), Bucherer-Bergs React
ion) (J. Prakt. Chem., 140 , 69 (1934)) or a modification thereof leads to a hydantoin derivative (5) or an aminocyanide derivative (6).
【0035】工程5:ヒダントイン誘導体(5)又はアミ
ノシアニド誘導体(6)は、R2−Y1−及びR3−Y2−の
組によって保護されたカルボニル基部位の脱保護、及
び、加水分解によって(±)、(+)又は(−)−2−アミノ
−4−オキソビシクロ[3.1.0]ヘキサン−2,6
−ジカルボン酸(7)に導かれる。Step 5: The hydantoin derivative (5) or the aminocyanide derivative (6) is obtained by deprotection of a carbonyl group site protected by a pair of R 2 —Y 1 — and R 3 —Y 2 — and hydrolysis. (±), (+) or (−)-2-amino-4-oxobicyclo [3.1.0] hexane-2,6
-To the dicarboxylic acid (7).
【0036】ここで、前記加水分解は、例えば塩酸、臭
化水素酸、硫酸等の酸を用いた酸性条件下、又は、例え
ば水酸化ナトリウム、水酸化カリウム、水酸化バリウム
等の塩基を用いた塩基性条件下で行うことができる。ま
た、カルボニル基部位の保護基の脱保護については、一
般的な脱保護条件を適宜用いることができる(Protectin
g Groups in Organic Synthesis(Theodora W. Greene
著、 John Wilely & Sons Inc.)参照)。更に、例えばR
2−Y1−とR3−Y2−が一緒になって−SCH2CH2S
−基を示す場合は、例えば硫酸を用いた酸加水分解条件
を採用することにより、ヒダントインあるいはアミノシ
アニド部分の加水分解と同時に−SCH 2CH2S−基を
除去することができる。Here, the hydrolysis is carried out by, for example, hydrochloric acid, odor, etc.
Under acidic conditions using acids such as hydrofluoric acid, sulfuric acid, or
Sodium hydroxide, potassium hydroxide, barium hydroxide
And the like, under basic conditions using a base such as Ma
For deprotection of the protecting group at the carbonyl group,
General deprotection conditions can be used as appropriate (Protectin
g Groups in Organic Synthesis (Theodora W. Greene
Author, John Wilely & Sons Inc.)). Further, for example, R
Two-Y1-And RThree-YTwo-Together-SCHTwoCHTwoS
-When indicating a group, for example, acid hydrolysis conditions using sulfuric acid
Hydantoin or amino acid
-SCH simultaneously with hydrolysis of the anide moiety TwoCHTwoS-group
Can be removed.
【0037】2−アミノ−4−オキソビシクロ[3.
1.0]ヘキサン−2,6−ジカルボン酸(7)は、1、
2、5及び6位に4つの不斉炭素原子が存在するので、
光学活性体、ラセミ体の2種のエナンチオマー混合物及
びジアステレオマーの混合物として存在できる。ここ
で、前記ジアステレオマーは、例えばシリカゲル等を用
いたカラムクロマトグラフィーや再結晶等の一般的な手
法によって分離することができる。そして、分離した各
ジアステレオマーは、例えば塩基性キラル分割剤を用い
た分割等の一般的な分割方法によって対応するエナンチ
オマーに分割できる。ここで、塩基性キラル分割剤と
は、例えば(+)又は(−)−1−フェニルエチルアミ
ン、(+)又は(−)−2−アミノ−1−ブタノール、
(+)又は(−)−アラニノール、ブルシン、シンコニ
ジン、シンコニン、キニン、キニジン、デヒドロアビエ
チルアミン等の光学活性なアミン類を示す。2-amino-4-oxobicyclo [3.
1.0] Hexane-2,6-dicarboxylic acid (7)
Since there are four asymmetric carbon atoms at positions 2, 5, and 6,
It can exist as a mixture of two enantiomers, optically active, racemic, and a mixture of diastereomers. Here, the diastereomers can be separated by a general technique such as column chromatography using silica gel or the like or recrystallization. Then, each separated diastereomer can be separated into the corresponding enantiomers by a common resolving method such as a resolution using a basic chiral resolving agent. Here, the basic chiral resolving agent is, for example, (+) or (−)-1-phenylethylamine, (+) or (−)-2-amino-1-butanol,
Optically active amines such as (+) or (−)-alaninol, brucine, cinchonidine, cinchonine, quinine, quinidine, dehydroabiethylamine and the like.
【0038】このようにして得られた2−アミノ−4−
オキソビシクロ[3.1.0]ヘキサン−2,6−ジカ
ルボン酸(7)は、医薬上許容される塩又は水和物の形態
で、例えば、担体、希釈剤又は賦形剤等と組み合わされ
て医薬用組成物として使用することができる。ここで、
医薬上許容される塩としては、例えば硫酸、塩酸、燐酸
などの鉱酸との塩、酢酸、シュウ酸、乳酸、酒石酸、フ
マール酸、マレイン酸、メタンスルホン酸、ベンゼンス
ルホン酸などの有機酸との塩、例えばトリメチルアミ
ン、メチルアミンなどのアミンとの塩、又はナトリウム
イオン、カリウムイオン、カルシウムイオンなどの金属
イオンとの塩等を挙げることができる。The thus obtained 2-amino-4-
Oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (7) is in the form of a pharmaceutically acceptable salt or hydrate, for example, in combination with a carrier, diluent or excipient. Can be used as a pharmaceutical composition. here,
Pharmaceutically acceptable salts include, for example, salts with mineral acids such as sulfuric acid, hydrochloric acid, and phosphoric acid, and organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methanesulfonic acid, and benzenesulfonic acid. And salts with amines such as trimethylamine and methylamine, and salts with metal ions such as sodium ion, potassium ion and calcium ion.
【0039】[0039]
【実施例】以下に本発明の代表的な実施例を示すが、本
発明はこれらに限定されるものではない。The present invention will be described in more detail with reference to the following Examples, which by no means limit the present invention.
【0040】実施例1:(1SR,4RS,5RS,6S
R)−エチル 4−tert−ブチルジメチルシリルオキシ
−2−オキソビシクロ[3.1.0]ヘキサン−6−カ
ルボキシレート、および、(1SR,4SR,5RS,6S
R)−エチル 4−tert−ブチルジメチルシリルオキシ
−2−オキソビシクロ[3.1.0]ヘキサン−6−カ
ルボキシレートの合成Embodiment 1: (1SR, 4RS, 5RS, 6S
R) -ethyl 4-tert-butyldimethylsilyloxy-2-oxobicyclo [3.1.0] hexane-6-carboxylate and (1SR, 4SR, 5RS, 6S
Synthesis of R) -ethyl 4-tert-butyldimethylsilyloxy-2-oxobicyclo [3.1.0] hexane-6-carboxylate
【0041】エチル (ジメチルスルファニリデン)アセ
タート13.6gのトルエン120mLの溶液に、4−t
ert−ブチルジメチルシリルオキシ−2−シクロペンテ
ノン18gの60mLトルエン溶液を氷冷下加えた。反
応を室温にて6時間攪拌した。反応混合物にさらにエチ
ル (ジメチルスルファニリデン)アセタート24.0g
のトルエン120mLの溶液を0℃で加え、室温にて一
昼夜攪拌した。反応液を1規定塩酸に注ぎ、分液した。
有機層を無水硫酸ナトリウムにて乾燥後、乾燥剤を濾別
し、減圧下濃縮した。残渣をシリカゲルカラムクロマト
グラフィー(ワコウゲルC200(和光純薬工業)、展開
溶媒;ヘキサン−酢酸エチル=15:1)にて精製し、
(1SR,4RS,5RS,6SR)−エチル 4−tert−
ブチルジメチルシリルオキシ−2−オキソビシクロ
[3.1.0]ヘキサン−6−カルボキシレートおよび
(1SR,4SR,5RS,6SR)−エチル 4−tert−
ブチルジメチルシリルオキシ−2−オキソビシクロ
[3.1.0]ヘキサン−6−カルボキシレートの混合
物19.0gを得た。To a solution of 13.6 g of ethyl (dimethylsulfanylidene) acetate in 120 mL of toluene was added 4-t
A solution of 18 g of ert-butyldimethylsilyloxy-2-cyclopentenone in 60 mL of toluene was added under ice cooling. The reaction was stirred at room temperature for 6 hours. The reaction mixture was further added with 24.0 g of ethyl (dimethylsulfanilidene) acetate.
Was added at 0 ° C., and the mixture was stirred at room temperature for 24 hours. The reaction solution was poured into 1N hydrochloric acid and separated.
After drying the organic layer over anhydrous sodium sulfate, the desiccant was filtered off and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Wako gel C200 (Wako Pure Chemical Industries, Ltd., developing solvent; hexane-ethyl acetate = 15: 1).
(1SR, 4RS, 5RS, 6SR) -ethyl 4-tert-
Butyldimethylsilyloxy-2-oxobicyclo [3.1.0] hexane-6-carboxylate and
(1SR, 4SR, 5RS, 6SR) -ethyl 4-tert-
19.0 g of a mixture of butyldimethylsilyloxy-2-oxobicyclo [3.1.0] hexane-6-carboxylate were obtained.
【0042】以下に、得られた化合物の1H−NMRス
ペクトルのデータを示す。1 H−NMR(CDCl3)δ(ppm);0.08(3H×5/8,
s),0.11(3H×3/8,s),0.90(9H×5/8,s),0.92(9H×3/8,
s),1.27(3H,t,J=7.3Hz),1.85(1H×5/8,dd,J=3.5,2.6H
z),1.92-2.70(4H+1H×3/8,m),4.17(2H×5/8,q,J=7.3H
z),4.20(2H×3/8,q,J=7.3Hz),4.52(1H×5/8,d,J=4.8H
z),4.73(1H×3/8,m)The data of 1 H-NMR spectrum of the obtained compound is shown below. 1 H-NMR (CDCl 3 ) δ (ppm); 0.08 (3H × 5/8,
s), 0.11 (3H x 3/8, s), 0.90 (9H x 5/8, s), 0.92 (9H x 3/8,
s), 1.27 (3H, t, J = 7.3Hz), 1.85 (1H x 5/8, dd, J = 3.5, 2.6H
z), 1.92-2.70 (4H + 1H × 3/8, m), 4.17 (2H × 5/8, q, J = 7.3H
z), 4.20 (2H x 3/8, q, J = 7.3Hz), 4.52 (1H x 5/8, d, J = 4.8H
z), 4.73 (1H × 3/8, m)
【0043】実施例2:(1RS,4RS,5RS,6R
S)−エチル 2,2−エチレンジチオ−4−ヒドロキシ
ビシクロ[3.1.0]ヘキサン−6−カルボキシレー
ト、および、(1RS,4SR,5RS,6RS)−エチル
2,2−エチレンジチオ−4−ヒドロキシビシクロ
[3.1.0]ヘキサン−6−カルボキシレートの合成Embodiment 2: (1RS, 4RS, 5RS, 6R
S) -ethyl 2,2-ethylenedithio-4-hydroxybicyclo [3.1.0] hexane-6-carboxylate and (1RS, 4SR, 5RS, 6RS) -ethyl 2,2-ethylenedithio-4 Of -Hydroxybicyclo [3.1.0] hexane-6-carboxylate
【0044】以下の反応は窒素雰囲気下行った。(1S
R,4RS,5RS,6SR)−エチル4−tert−ブチルジ
メチルシリルオキシ−2−オキソビシクロ[3.1.
0]ヘキサン−6−カルボキシレートおよび(1SR,4
SR,5RS,6SR)−エチル 4−tert−ブチルジメ
チルシリルオキシ−2−オキソビシクロ[3.1.0]
ヘキサン−6−カルボキシレートの混合物16.8gと
エタンジチオール5.7mLの塩化メチレン168mL
溶液に、三フッ化ホウ素ジエチルエーテル錯体2.1m
Lを室温にて加え、2日間攪拌した。反応液を減圧下濃
縮し、残渣を飽和炭酸水素ナトウリム水溶液とクロロホ
ルムにて分液した。有機層を無水硫酸ナトリウムにて乾
燥後、乾燥剤を濾別し、減圧下濃縮した。残渣をシリカ
ゲルカラムクロマトグラフィー(ワコウゲルC200(和
光純薬工業)、展開溶媒;ヘキサン−酢酸エチル=4:
1〜2:1)にて精製し、(1RS,4RS,5RS,6R
S)−エチル 2,2−エチレンジチオ−4−ヒドロキシ
ビシクロ[3.1.0]ヘキサン−6−カルボキシレー
トおよび(1RS,4SR,5RS,6RS)−エチル2,2
−エチレンジチオ−4−ヒドロキシビシクロ[3.1.
0]ヘキサン−6−カルボキシレートの混合物13.7g
を得た。The following reactions were performed in a nitrogen atmosphere. (1S
R, 4RS, 5RS, 6SR) -ethyl 4-tert-butyldimethylsilyloxy-2-oxobicyclo [3.1.
0] hexane-6-carboxylate and (1SR, 4
SR, 5RS, 6SR) -Ethyl 4-tert-butyldimethylsilyloxy-2-oxobicyclo [3.1.0]
16.8 g of a mixture of hexane-6-carboxylate and 5.7 mL of ethanedithiol 168 mL of methylene chloride
In the solution, boron trifluoride diethyl ether complex 2.1m
L was added at room temperature and stirred for 2 days. The reaction solution was concentrated under reduced pressure, and the residue was separated with a saturated aqueous solution of sodium bicarbonate and chloroform. After drying the organic layer over anhydrous sodium sulfate, the desiccant was filtered off and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (Wako gel C200 (Wako Pure Chemical Industries, Ltd.), developing solvent: hexane-ethyl acetate = 4:
(1RS, 4RS, 5RS, 6R)
S) -Ethyl 2,2-ethylenedithio-4-hydroxybicyclo [3.1.0] hexane-6-carboxylate and (1RS, 4SR, 5RS, 6RS) -ethyl 2,2
-Ethylenedithio-4-hydroxybicyclo [3.1.
0] 13.7 g of a mixture of hexane-6-carboxylate
I got
【0045】以下に、得られた化合物の1H−NMRス
ペクトルのデータを示す。1 H−NMR(CDCl3)δ(ppm);1.26(3H×5/8,t,
J=7.1Hz),1.28(3H×3/8,t,J=7.1Hz),1.53(1H×5/8,t,J=
3.1Hz),1.70-2.54(5H+1H×3/8,m),3.28-3.50(4H,m),4.1
3(2H×3/8,q,J=7.1Hz),4.14(2H×5/8,q,J=7.1Hz),4.36
(1H×5/8,dd,J=7.5,4.8Hz),4.64(1H×3/8,m)The data of 1 H-NMR spectrum of the obtained compound is shown below. 1 H-NMR (CDCl 3) δ (ppm); 1.26 (3H × 5/8, t,
J = 7.1Hz), 1.28 (3H × 3/8, t, J = 7.1Hz), 1.53 (1H × 5/8, t, J =
3.1Hz), 1.70-2.54 (5H + 1H × 3/8, m), 3.28-3.50 (4H, m), 4.1
3 (2H × 3/8, q, J = 7.1Hz), 4.14 (2H × 5/8, q, J = 7.1Hz), 4.36
(1H × 5/8, dd, J = 7.5,4.8Hz), 4.64 (1H × 3/8, m)
【0046】実施例3:(1RS,5RS,6RS)−エチ
ル 4,4−エチレンジチオ−2−オキソビシクロ
[3.1.0]ヘキサン−6−カルボキシレートの合成Example 3 Synthesis of (1RS, 5RS, 6RS) -ethyl 4,4-ethylenedithio-2-oxobicyclo [3.1.0] hexane-6-carboxylate
【0047】(1RS,4RS,5RS,6RS)−エチル
2,2−エチレンジチオ−4−ヒドロキシビシクロ
[3.1.0]ヘキサン−6−カルボキシレートおよび
(1RS,4SR,5RS,6RS)−エチル 2,2−エチ
レンジチオ−4−ヒドロキシビシクロ[3.1.0]ヘ
キサン−6−カルボキシレートの混合物13.1gのジメ
チルスルホキシド520mL溶液に、40.5gのジシ
クロヘキシルカルボジイミド、5.0mLのピリジンお
よび2.8mLのトリフルオロ酢酸を15℃にて順次加
えた。反応液を室温にて一昼夜撹拌後、析出した固体を
濾別し、酢酸エチルにて固体を洗浄した。濾液と洗浄液
を併せて水に注ぎ、クロロホルムにて抽出した。有機層
を水にて3回洗浄し、無水硫酸ナトリウムにて乾燥し
た。乾燥剤を濾別後、減圧下濃縮し、残渣をシリカゲル
カラムクロマトグラフィー(ワコウゲルC200(和光純
薬工業)、展開溶媒;ヘキサン−酢酸エチル=5:1)に
て精製し、(1RS,5RS,6RS)−エチル 4,4−
エチレンジチオ−2−オキソビシクロ[3.1.0]ヘ
キサン−6−カルボキシレート10.5gを得た。(1RS, 4RS, 5RS, 6RS) -ethyl 2,2-ethylenedithio-4-hydroxybicyclo [3.1.0] hexane-6-carboxylate and
To a solution of 13.1 g of a mixture of (1RS, 4SR, 5RS, 6RS) -ethyl 2,2-ethylenedithio-4-hydroxybicyclo [3.1.0] hexane-6-carboxylate in 520 mL of dimethyl sulfoxide was added 40.5 g. Of dicyclohexylcarbodiimide, 5.0 mL of pyridine and 2.8 mL of trifluoroacetic acid were sequentially added at 15 ° C. After stirring the reaction solution at room temperature for 24 hours, the precipitated solid was separated by filtration and washed with ethyl acetate. The combined filtrate and washings were poured into water and extracted with chloroform. The organic layer was washed three times with water and dried over anhydrous sodium sulfate. After the desiccant was separated by filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (Wako gel C200 (Wako Pure Chemical Industries, Ltd., developing solvent; hexane-ethyl acetate = 5: 1)) to give (1RS, 5RS, 6RS) -Ethyl 4,4-
10.5 g of ethylenedithio-2-oxobicyclo [3.1.0] hexane-6-carboxylate were obtained.
【0048】以下に、得られた化合物の1H−NMR及
びMSスペクトルのデータを示す。1 H−NMR(CDCl3)δ(ppm);1.29(3H,t,J=7.1H
z),2.25(1H,dd,J=3.3,2.8Hz),2.53(1H,dd,J=5.5,2.8H
z),2.75(2H,s),3.01(1H,dd,J=5.5,3.3Hz),3.37-3.53(4
H,m),4.18(2H,dq,J=2.2,7.1Hz) MS(FAB)(Pos.)m/e;259(M++1)The following shows 1 H-NMR and MS spectrum data of the obtained compound. 1 H-NMR (CDCl 3) δ (ppm); 1.29 (3H, t, J = 7.1H
z), 2.25 (1H, dd, J = 3.3,2.8Hz), 2.53 (1H, dd, J = 5.5,2.8H
z), 2.75 (2H, s), 3.01 (1H, dd, J = 5.5,3.3Hz), 3.37-3.53 (4
H, m), 4.18 (2H, dq, J = 2.2, 7.1 Hz) MS (FAB) (Pos.) M / e; 259 (M ++ 1)
【0049】なお、(1RS,5RS,6RS)−エチル
4,4−エチレンジチオ−2−オキソビシクロ[3.
1.0]ヘキサン−6−カルボキシレートはHPLC(C
HIRALPAK AD 0.46*25cm(ダイセル化学工業)、Elue
nt:n−ヘキサン/2−プロパノール=3:1、Fl
ow rate:1.0mL/min、Temp.:r
t.、Detect:UV210nm)にて(1R* ,5R*
,6R*)−エチル 4,4−エチレンジチオ−2−オキ
ソビシクロ[3.1.0]ヘキサン−6−カルボキシレ
ート(tR:7.65min.)および(1R* ,5R* ,6
R*)−エチル 4,4−エチレンジチオ−2−オキソビ
シクロ[3.1.0]ヘキサン−6−カルボキシレート
(tR:9.17min.)にそれぞれ光学分割することが
できる。(1RS, 5RS, 6RS) -ethyl
4,4-ethylenedithio-2-oxobicyclo [3.
1.0] Hexane-6-carboxylate was prepared by HPLC (C
HIRALPAK AD 0.46 * 25cm (Daicel Chemical Industries), Elue
nt: n-hexane / 2-propanol = 3: 1, Fl
ow rate: 1.0 mL / min, Temp .: r
t., Detect: UV210nm) (1R * , 5R *)
, 6R *) - Ethyl 4,4-ethylenedithio-2-oxobicyclo [3.1.0] hexane-6-carboxylate (t R:. 7.65min) and (1R *, 5R *, 6
R * )-Ethyl 4,4-ethylenedithio-2-oxobicyclo [3.1.0] hexane-6-carboxylate
(t R : 9.17 min.).
【0050】実施例4:(1RS,2SR,5RS,6R
S)−エチル 2−スピロ−5'−ヒダントイン−4,4
−エチレンジチオビシクロ[3.1.0]ヘキサン−6
−カルボキシレートの合成Embodiment 4: (1RS, 2SR, 5RS, 6R
S) -Ethyl 2-spiro-5'-hydantoin-4,4
-Ethylenedithiobicyclo [3.1.0] hexane-6
-Synthesis of carboxylate
【0051】(1RS,5RS,6RS)−エチル 4,4
−エチレンジチオ−2−オキソビシクロ[3.1.0]
ヘキサン−6−カルボキシレート73.2g、炭酸アン
モニウム68.1gおよびシアン化カリウム20.8gの
混合物をエタノール460mL−水307mLの混合溶
媒中35℃にて3日間撹拌した。反応混合物を0℃にて
2時間撹拌し、析出した固体を濾取した。得られた固体
をクロロホルム−メタノール(9:1)の混合溶媒1.1
L中65℃にて1.5時間攪拌後、室温まで冷却し、結
晶を濾取した。この結晶をクロロホルム−メタノール
(9:1)の混合溶媒100mLにて同様の操作を行い、
(1RS,2SR,5RS,6RS)−エチル2−スピロ−
5'−ヒダントイン−4,4−エチレンジチオビシクロ
[3.1.0]ヘキサン−6−カルボキシレート35.
2gを得た。(1RS, 5RS, 6RS) -ethyl 4,4
-Ethylenedithio-2-oxobicyclo [3.1.0]
A mixture of 73.2 g of hexane-6-carboxylate, 68.1 g of ammonium carbonate and 20.8 g of potassium cyanide was stirred in a mixed solvent of 460 mL of ethanol-307 mL of water at 35 ° C. for 3 days. The reaction mixture was stirred at 0 ° C. for 2 hours, and the precipitated solid was collected by filtration. The obtained solid was mixed with chloroform-methanol (9: 1) mixed solvent 1.1.
After stirring at 65 ° C. for 1.5 hours in L, the mixture was cooled to room temperature and the crystals were collected by filtration. The crystals are chloroform-methanol
The same operation was performed with 100 mL of the mixed solvent (9: 1),
(1RS, 2SR, 5RS, 6RS) -ethyl 2-spiro-
5'-hydantoin-4,4-ethylenedithiobicyclo [3.1.0] hexane-6-carboxylate 35.
2 g were obtained.
【0052】以下に、得られた化合物の1H−NMR及
びMSスペクトルのデータを示す。1 H−NMR(DMSO-d6)δ(ppm);1.20(3H,t,J=7.0Hz),2.
00(1H,t,J=3.1Hz),2.21(1H,d,J=16Hz),2.25-2.29(1H,m,
J=3.1Hz),2.46(1H,dd,J=6.2Hz,3.1Hz),2.60(1H,d,J=16H
z),3.20-3.42(4H,m),4.07(2H,q,J=7.0Hz),7.91(1H,s),1
0.70(1H,s).MS(Ion Spray)(Nega)m/
e;327(M+-1)The following shows 1 H-NMR and MS spectrum data of the obtained compound. 1 H-NMR (DMSO-d 6 ) δ (ppm); 1.20 (3H, t, J = 7.0 Hz), 2.
00 (1H, t, J = 3.1Hz), 2.21 (1H, d, J = 16Hz), 2.25-2.29 (1H, m,
J = 3.1Hz), 2.46 (1H, dd, J = 6.2Hz, 3.1Hz), 2.60 (1H, d, J = 16H
z), 3.20-3.42 (4H, m), 4.07 (2H, q, J = 7.0Hz), 7.91 (1H, s), 1
0.70 (1H, s) .MS (Ion Spray) (Nega) m /
e; 327 (M + -1)
【0053】実施例5:(+)−(1S,2S,5R,6R)
−2−アミノ−4−オキソビシクロ[3.1.0]ヘキ
サン−2,6−ジカルボン酸の合成Example 5: (+)-(1S, 2S, 5R, 6R)
Synthesis of -2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
【0054】(1)(1RS,2SR,5RS,6RS)−
エチル 2−スピロ−5´−ヒダントイン−4,4−エ
チレンジチオビシクロ[3.1.0]ヘキサン−6−カ
ルボキシレート2.10gと2規定水酸化ナトリウム水
溶液13mlの混合物を室温で1時間攪拌後、濃塩酸を
加えpHを1.0に調整した。生成した結晶を濾別し、
水70mlで洗浄し、乾燥して(1RS,2SR,5RS,
6RS)−2−スピロ−5´−ヒダントイン−4,4−エ
チレンジチオビシクロ[3.1.0]ヘキサン−6−カ
ルボン酸1.87gを得た。 (2)(1RS,2SR,5RS,6RS)−2−スピロ−5
´−ヒダントイン−4,4−エチレンジチオビシクロ
[3.1.0]ヘキサン−6−カルボン酸1.87gと
(R)−(+)−1−フェニルエチルアミン0.91gをN,
N−ジメチルホルムアミド50mlに溶解し、1−ヒド
ロキシベンゾトリアゾール1水和物1.05gと1−エ
チル−3−(3−ジメチルアミノプロピル)カルボジイミ
ド 塩酸塩1.43gを氷冷下加え、室温で14時間撹拌
した。1規定塩酸に反応溶液を加え、酢酸エチルで抽出
後、無水硫酸ナトリウムで乾燥し、乾燥剤を濾別後、減
圧下濃縮した。残渣をシリカゲルカラムクロマトグラフ
ィー(シリカゲル:MSG40−60A(洞海化学工
業)、展開溶媒:クロロホルム−メタノール=40:1
〜25:1)に付し、(1S,2R,5S,6S)−2−スピ
ロ−5´−ヒダントイン−4,4−エチレンジチオ−N
−((R)−1−フェニルエチル)−ビシクロ[3.1.
0]ヘキサン−6−カルボキシアミド(Rf値0.54
(TLC:シリカゲル 60F254(メルク製)、展開溶
媒:クロロホルム−メタノール=9:1))1.17gと
(1R,2S,5R,6R)−2−スピロ−5´−ヒダント
イン−4,4−エチレンジチオ−N−((R)−1−フェニ
ルエチル)−ビシクロ[3.1.0]ヘキサン−6−カ
ルボキシアミド(Rf値0.51(TLC:シリカゲル 6
0 F254(メルク製)、展開溶媒:クロロホルム−メタ
ノール=9:1))1.10gに分離した。 (3)上記(2)で得た(1R,2S,5R,6R)−2−ス
ピロ−5´−ヒダントイン−4,4−エチレンジチオ−
N−((R)−1−フェニルエチル)[3.1.0]ヘキサ
ン−6−カルボキシアミド1.10gを60%(w/v
%)硫酸水溶液20mLに懸濁し、145℃で4日間撹
拌した。反応溶液を室温まで冷却後、5規定水酸化ナト
リウム水溶液でpH7にした後、イオン交換クロマトグ
ラフィー(AG1−X8 陰イオン交換樹脂(Bio−R
ad)、OH-型、溶出溶媒:水〜50%テトラヒドロフ
ラン−水〜水〜30%酢酸水溶液)に付し結晶を0.37
g得た。この結晶にアセトン10mlを加え、室温で2
時間撹拌後、結晶を濾別し、アセトン5ml、テトラヒ
ドロフラン5ml及びアセトン5mlで洗浄後、乾燥
し、(+)−(1S,2S,5R,6R)−2−アミノ−4−
オキソビシクロ[3.1.0]ヘキサン−2,6−ジカ
ルボン酸0.30gを得た。(1) (1RS, 2SR, 5RS, 6RS)-
A mixture of 2.10 g of ethyl 2-spiro-5'-hydantoin-4,4-ethylenedithiobicyclo [3.1.0] hexane-6-carboxylate and 13 ml of 2N aqueous sodium hydroxide solution was stirred at room temperature for 1 hour. , Concentrated hydrochloric acid was added to adjust the pH to 1.0. The generated crystals are filtered off,
Wash with 70 ml of water, dry (1RS, 2SR, 5RS,
1.87 g of 6RS) -2-spiro-5'-hydantoin-4,4-ethylenedithiobicyclo [3.1.0] hexane-6-carboxylic acid was obtained. (2) (1RS, 2SR, 5RS, 6RS) -2-spiro-5
1.87 g of '-hydantoin-4,4-ethylenedithiobicyclo [3.1.0] hexane-6-carboxylic acid
0.91 g of (R)-(+)-1-phenylethylamine was added to N,
The residue was dissolved in 50 ml of N-dimethylformamide, and 1.05 g of 1-hydroxybenzotriazole monohydrate and 1.43 g of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added under ice-cooling. Stirred for hours. The reaction solution was added to 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue is subjected to silica gel column chromatography (silica gel: MSG40-60A (Dokai Chemical Industry), developing solvent: chloroform-methanol = 40: 1).
2525: 1) and (1S, 2R, 5S, 6S) -2-spiro-5′-hydantoin-4,4-ethylenedithio-N
-((R) -1-phenylethyl) -bicyclo [3.1.
0] hexane-6-carboxamide (Rf value 0.54
(TLC: silica gel 60F 254 (Merck), developing solvent: chloroform - methanol = 9: 1)) 1.17 g and
(1R, 2S, 5R, 6R) -2-spiro-5'-hydantoin-4,4-ethylenedithio-N-((R) -1-phenylethyl) -bicyclo [3.1.0] hexane-6 -Carboxamide (Rf 0.51 (TLC: silica gel 6
0F 254 (manufactured by Merck), developing solvent: chloroform-methanol = 9: 1)). (3) (1R, 2S, 5R, 6R) -2-spiro-5'-hydantoin-4,4-ethylenedithio- obtained in (2) above.
1.10 g of N-((R) -1-phenylethyl) [3.1.0] hexane-6-carboxamide was added to 60% (w / v).
%) Aqueous sulfuric acid solution (20 mL) and stirred at 145 ° C. for 4 days. The reaction solution was cooled to room temperature, adjusted to pH 7 with a 5N aqueous sodium hydroxide solution, and then subjected to ion exchange chromatography (AG1-X8 anion exchange resin (Bio-R).
ad), OH - type, eluting solvent: water to 50% tetrahydrofuran-water to water to 30% acetic acid aqueous solution) to give 0.37 crystals.
g was obtained. 10 ml of acetone was added to the crystals, and
After stirring for an hour, the crystals were separated by filtration, washed with 5 ml of acetone, 5 ml of tetrahydrofuran and 5 ml of acetone, dried and dried to give (+)-(1S, 2S, 5R, 6R) -2-amino-4-.
0.30 g of oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid was obtained.
【0055】以下に、得られた化合物の1H−NMR、
MSスペクトル及び比施光度のデータを示す。1 H−NMR(pyridine-d5/D2O=1/1)δ(ppm);2.86
(1H,dd,J=3.5Hz,2.7Hz),2.93(1H,d,J=18Hz),3.00(1H,d
d,J=5.7Hz,2.7Hz),3.05(1H,d,J=18Hz),3.30(1H,dd,J=5.
7Hz,3.5Hz) MS(FAB)(Nega.)m/e;198(M+-1) [α]D 32=+43.06(c=0.20,H2O)Hereinafter, 1 H-NMR of the obtained compound,
The data of MS spectrum and specific light intensity are shown. 1 H-NMR (pyridine-d 5 / D 2 O = 1/1) δ (ppm); 2.86
(1H, dd, J = 3.5Hz, 2.7Hz), 2.93 (1H, d, J = 18Hz), 3.00 (1H, d
d, J = 5.7Hz, 2.7Hz), 3.05 (1H, d, J = 18Hz), 3.30 (1H, dd, J = 5.
7 Hz, 3.5 Hz) MS (FAB) (Nega.) M / e; 198 (M + -1) [α] D 32 = +43.06 (c = 0.20, H 2 O)
【0056】[0056]
【発明の効果】本発明化合物である、ビシクロ[3.
1.0]ヘキサン−6−カルボン酸誘導体は、精神分裂
病、不安及びその関連疾患、うつ病、二極性障害、てん
かん等の精神医学的障害、また、薬物依存症、認知障
害、アルツハイマー病、ハンチントン舞踏病、パーキン
ソン病、筋硬直に伴う運動障害、脳虚血、脳不全、脊髄
障害、頭部障害等の神経学的疾患に治療効果及び予防効
果を有するグループ2メタボトロピックグルタミン酸受
容体に作用する4−置換−2−アミノビシクロ[3.
1.0]ヘキサン−2,6−ジカルボン酸の合成中間原
料として有用である。The compound of the present invention, bicyclo [3.
1.0] Hexane-6-carboxylic acid derivatives are useful for schizophrenia, anxiety and related diseases, depression, bipolar disorder, psychiatric disorders such as epilepsy, drug dependence, cognitive disorders, Alzheimer's disease, Acts on group 2 metabotropic glutamate receptors with therapeutic and preventive effects on neurological diseases such as Huntington's chorea, Parkinson's disease, motor dysfunction associated with muscle stiffness, cerebral ischemia, cerebral insufficiency, spinal cord injury, head injury 4-substituted-2-aminobicyclo [3.
1.0] It is useful as an intermediate material for the synthesis of hexane-2,6-dicarboxylic acid.
【0057】そして、2−オキソビシクロ[3.1.
0]ヘキサン−6−カルボン酸誘導体を出発原料として
使用した場合には、2−アミノ−4−オキソビシクロ
[3.1.0]ヘキサン−2,6−ジカルボン酸を効率
的に製造することが可能となり、特に光学活性体を高収
率で合成することができる。Then, 2-oxobicyclo [3.1.
When 0] hexane-6-carboxylic acid derivative is used as a starting material, 2-amino-4-oxobicyclo [3.1.0] hexane-2,6-dicarboxylic acid can be efficiently produced. This makes it possible to synthesize an optically active substance with a high yield.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 坂上 一成 東京都豊島区高田3−24−1 大正製薬株 式会社内 (72)発明者 冨沢 一雪 東京都豊島区高田3−24−1 大正製薬株 式会社内 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Kazunari Sakagami 3-24-1, Takada, Toshima-ku, Tokyo Inside Taisho Pharmaceutical Co., Ltd. (72) Inventor Kazuki Tomizawa 3-24-1, Takada, Toshima-ku, Tokyo Taisho Within a pharmaceutical company
Claims (3)
6シクロアルキル基、C3〜C6シクロアルキルC1〜C6
アルキル基、アリール基、アリールC1〜C6アルキル
基、C1〜C6アルコキシC1〜C6アルキル基、C1〜C6
ヒドロキシアルキル基、C1〜C6アルキルチオC1〜C6
アルキル基、C1〜C6メルカプトアルキル基、テトラヒ
ドロフラニル基又はテトラヒドロピラニル基を示す。R
2とR3は同一又は異なってC1〜C6アルキル基、C3〜
C6シクロアルキル基、C3〜C6シクロアルキルC1〜C
6アルキル基、アリール基又はアリールC1〜C6アルキ
ル基を示すか、或いは一緒になって−(CH2)n−(n
は2又は3)を示す。Y1及びY2は同一又は異なって硫
黄原子、酸素原子又は窒素原子を示す。]で表される2
−オキソビシクロ[3.1.0]ヘキサン−6−カルボ
ン酸誘導体。(1) Formula (1) [Wherein, R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 3 -C
6 cycloalkyl groups, C 3 -C 6 cycloalkyl C 1 -C 6
Alkyl group, aryl group, aryl C 1 -C 6 alkyl group, C 1 -C 6 alkoxy C 1 -C 6 alkyl group, C 1 -C 6
Hydroxyalkyl group, C 1 -C 6 alkylthio C 1 -C 6
It represents an alkyl group, a C 1 -C 6 mercaptoalkyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group. R
2 and R 3 are identical or different C 1 -C 6 alkyl group, C 3 ~
C 6 cycloalkyl group, C 3 -C 6 cycloalkyl C 1 -C
A 6 alkyl group, an aryl group or an aryl C 1 -C 6 alkyl group, or together form — (CH 2 ) n — (n
Represents 2 or 3). Y 1 and Y 2 are the same or different and represent a sulfur atom, an oxygen atom or a nitrogen atom. 2]
-Oxobicyclo [3.1.0] hexane-6-carboxylic acid derivative.
で表されるシクロペンテノン誘導体に、Me2S=CHC
O2R5[式中、R5はC1〜C6アルキル基、C3〜C6シ
クロアルキル基、C3〜C6シクロアルキルC1〜C6アル
キル基、アリール基、アリールC1〜C6アルキル基、C
1〜C6アルコキシC1〜C6アルキル基、C 1〜C6ヒドロ
キシアルキル基、C1〜C6アルキルチオC1〜C6アルキ
ル基、C1〜C6メルカプトアルキル基、テトラヒドロフ
ラニル基又はテトラヒドロピラニル基を示す。]で表さ
れるスルホニウムイリドを反応させるか、又は、Me2S
+CH2CO2R5・X-[式中、R5は前記と同様である。
Xは塩素原子、臭素原子又はヨウ素原子を示す。]で表
されるスルホニウム塩を反応させることによって、式
(3) 【化3】 [式中、R4、R5は前記と同様である。]で表される二
環式化合物とする工程と、 前記二環式化合物のカルボニル基を保護することによっ
て、式(4) 【化4】 [式中、R2とR3は同一又は異なってC1〜C6アルキル
基、アリール基又はアリールC1〜C6アルキル基を示す
か、或いは一緒になって−(CH2)n−(nは2又は
3)を示す。Y1及びY2は同一又は異なって硫黄原子、
酸素原子又は窒素原子を示す。R4及びR5は前記と同様
である。]で表される誘導体とする工程と、 前記誘導体のR4が水素原子以外の場合はR4を水素原子
に変換後、前記誘導体を酸化する工程とを含む、請求項
1記載のカルボン酸誘導体の製造方法。(2) Formula (2)[Wherein, RFourRepresents a hydrogen atom or a hydroxyl-protecting group. ]
To the cyclopentenone derivative represented byTwoS = CHC
OTwoRFive[Wherein, RFiveIs C1~ C6Alkyl group, CThree~ C6Shi
Chloroalkyl group, CThree~ C6Cycloalkyl C1~ C6Al
Kill group, aryl group, aryl C1~ C6Alkyl group, C
1~ C6Alkoxy C1~ C6Alkyl group, C 1~ C6Hydro
Xyalkyl group, C1~ C6Alkylthio C1~ C6Archi
Group, C1~ C6Mercaptoalkyl group, tetrahydrof
It represents a lanyl group or a tetrahydropyranyl group. ]
Or reacting the sulfonium ylideTwoS
+CHTwoCOTwoRFive・ X-[Wherein, RFiveIs the same as above.
X represents a chlorine atom, a bromine atom or an iodine atom. ]
By reacting the sulfonium salt
(3)[Wherein, RFour, RFiveIs the same as above. ]
Forming a cyclic compound, and protecting the carbonyl group of the bicyclic compound.
And formula (4)[Wherein, RTwoAnd RThreeAre the same or different C1~ C6Alkyl
Group, aryl group or aryl C1~ C6Indicates an alkyl group
Together or-(CHTwo)n-(N is 2 or
3) is shown. Y1And YTwoAre the same or different sulfur atoms,
Indicates an oxygen atom or a nitrogen atom. RFourAnd RFiveIs the same as above
It is. A process represented by the formula:FourIs other than a hydrogen atom, RFourIs the hydrogen atom
Oxidizing the derivative after conversion to
2. A method for producing the carboxylic acid derivative according to 1.
6シクロアルキル基、C3〜C6シクロアルキルC1〜C6
アルキル基、アリール基、アリールC1〜C6アルキル
基、C1〜C6アルコキシC1〜C6アルキル基、C1〜C6
ヒドロキシアルキル基、C1〜C6アルキルチオC1〜C6
アルキル基、C1〜C6メルカプトアルキル基、テトラヒ
ドロフラニル基又はテトラヒドロピラニル基を示す。R
2とR3は同一又は異なってC1〜C6アルキル基、C3〜
C6シクロアルキル基、C3〜C6シクロアルキルC1〜C
6アルキル基、アリール基又はアリールC1〜C6アルキ
ル基を示すか、或いは一緒になって−(CH2)n−(n
は2又は3)を示す。Y1及びY2は同一又は異なって硫
黄原子、酸素原子又は窒素原子を示す。]で表されるビ
シクロ[3.1.0]ヘキサン−6−カルボン酸誘導
体。(3) Formula (5) [Wherein, R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 3 -C
6 cycloalkyl groups, C 3 -C 6 cycloalkyl C 1 -C 6
Alkyl group, aryl group, aryl C 1 -C 6 alkyl group, C 1 -C 6 alkoxy C 1 -C 6 alkyl group, C 1 -C 6
Hydroxyalkyl group, C 1 -C 6 alkylthio C 1 -C 6
It represents an alkyl group, a C 1 -C 6 mercaptoalkyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group. R
2 and R 3 are identical or different C 1 -C 6 alkyl group, C 3 ~
C 6 cycloalkyl group, C 3 -C 6 cycloalkyl C 1 -C
A 6 alkyl group, an aryl group or an aryl C 1 -C 6 alkyl group, or together form — (CH 2 ) n — (n
Represents 2 or 3). Y 1 and Y 2 are the same or different and represent a sulfur atom, an oxygen atom or a nitrogen atom. And a bicyclo [3.1.0] hexane-6-carboxylic acid derivative represented by the formula:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000044940A JP4505926B2 (en) | 1999-03-25 | 2000-02-22 | NOVEL CARBOXYLIC ACID DERIVATIVE AND METHOD FOR PRODUCING THE SAME |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11-82608 | 1999-03-25 | ||
JP8260899 | 1999-03-25 | ||
JP2000044940A JP4505926B2 (en) | 1999-03-25 | 2000-02-22 | NOVEL CARBOXYLIC ACID DERIVATIVE AND METHOD FOR PRODUCING THE SAME |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000336068A true JP2000336068A (en) | 2000-12-05 |
JP4505926B2 JP4505926B2 (en) | 2010-07-21 |
Family
ID=26423637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000044940A Expired - Fee Related JP4505926B2 (en) | 1999-03-25 | 2000-02-22 | NOVEL CARBOXYLIC ACID DERIVATIVE AND METHOD FOR PRODUCING THE SAME |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4505926B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154291A (en) * | 2003-11-21 | 2005-06-16 | Ajinomoto Co Inc | Organic amine salt of glutamic acid derivative and its use |
JP2010241815A (en) * | 2010-06-01 | 2010-10-28 | Ajinomoto Co Inc | Organic amine salt of glutamic acid derivative, and use of the organic amine salt |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0774454A1 (en) * | 1995-11-16 | 1997-05-21 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
EP0878463B1 (en) * | 1997-05-14 | 2000-12-20 | Eli Lilly And Company | Excitatory amino acid receptor modulators |
-
2000
- 2000-02-22 JP JP2000044940A patent/JP4505926B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
EP0774454A1 (en) * | 1995-11-16 | 1997-05-21 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP0878463B1 (en) * | 1997-05-14 | 2000-12-20 | Eli Lilly And Company | Excitatory amino acid receptor modulators |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154291A (en) * | 2003-11-21 | 2005-06-16 | Ajinomoto Co Inc | Organic amine salt of glutamic acid derivative and its use |
JP2010241815A (en) * | 2010-06-01 | 2010-10-28 | Ajinomoto Co Inc | Organic amine salt of glutamic acid derivative, and use of the organic amine salt |
Also Published As
Publication number | Publication date |
---|---|
JP4505926B2 (en) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2341865C (en) | 6-fluorobicyclo[3.1.0]hexane derivatives | |
AU734812B2 (en) | Fluorine-containing amino acid derivatives | |
JP4194715B2 (en) | 6-Fluorobicyclo [3.1.0] hexane derivative | |
EP0774461B1 (en) | Excitatory amino acid derivatives | |
JP4505926B2 (en) | NOVEL CARBOXYLIC ACID DERIVATIVE AND METHOD FOR PRODUCING THE SAME | |
EP1164121B1 (en) | Novel carboxylic acid derivatives and process for producing the same | |
JPH11279129A (en) | Fluoroamino acid derivative | |
AU2004289652B8 (en) | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto | |
JP4124656B2 (en) | Method for producing bicyclocarboxylic acid derivative | |
JP4399932B2 (en) | Intermediate and method for producing fluorine-containing amino acid compound using the same | |
WO2002000595A1 (en) | Intermediate and process for producing fluorinated carboxylic acid derivative from the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100406 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100419 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140514 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |